Crohn's Disease Market: By Procedures (Colonoscopy, Flexible Sigmoidoscopy, Computerized Tomography (CT), Magnetic Resonance Imaging (MRI), Capsule Endoscopy, Double-Balloon Endoscopy, Small Bowel Imaging), By Therapeutic Type (Non-surgical, Surgical), By End User (Hospitals and Clinics, Research Institutes, Diagnostic Centres and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online and Others), and Geography 

Purchase Option

$ 4400
$ 6600
$ 8900

Crohn’s Disease Market valued at USD 10,783.6 million in 2022 and is expected to grow at 5.1% CAGR over the forecast years 2023 – 2029. Crohn's Disease is characterized by inflammation in the gastrointestinal tract, causing symptoms such as abdominal pain, diarrhea, weight loss, and fatigue. According to report findings 2021, the prevalence of Crohn's Disease has been on the rise worldwide, affecting approximately 3.2 per 1,000 individuals in the United States and around 322 per 100,000 individuals in Europe. In Europe, the incidence of Crohn's Disease varies among countries, with the highest reported rates in Northern Europe. Furthermore, the European healthcare system faces substantial economic consequences due to this disease, with estimates indicating that direct medical costs surpass €5,000 per patient per year.

In recent years, the Crohn's Disease market has witnessed a surge in research and development activities, leading to the emergence of targeted biologic therapies. These therapies, such as anti-TNF agents and integrin receptor antagonists, have shown promising results in inducing and maintaining remission, improving patients' quality of life. Moreover, ongoing research explores the potential of novel treatments, including JAK inhibitors and stem cell therapies, indicating a promising future for patients with Crohn's Disease. Additionally, advancements in telemedicine and digital health technologies have facilitated better remote patient monitoring and disease management, empowering individuals to access healthcare services more conveniently. The integration of artificial intelligence and data analytics in managing Crohn's Disease has shown potential in predicting disease flares and optimizing treatment strategies for improved patient outcomes.

Crohn’s Disease Market Key Developments:
  • In June 2022, AbbVie Inc., a biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved SKYRIZI (Risankizumab) as the first and only specific interleukin-23 (IL-23) inhibitor for the treatment of adults with moderately to severely active Crohn's disease (CD).
  • In March 2022, Tiziana Life Sciences, a biotechnology company, commenced a Phase Ib clinical trial of oral enteric-coated capsules of Foralumab (TZLS-401), a monoclonal antibody (mAb), in mild-to-moderate Crohn’s disease (CD) patients.

Crohns Disease Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

5.1%

Largest Market

North America

Fastest Growing Market

North America
Crohn’s Disease Market Dynamics

Crohn's disease, a chronic inflammatory bowel disorder, is experiencing significant market dynamics, driven by various factors that contribute to its growth and present promising opportunities for stakeholders. The rising prevalence of Crohn's disease globally, coupled with an increasing aging population, has fueled the demand for effective treatment options and innovative therapies. Additionally, advancements in medical research and technology have led to the development of novel biologics and targeted therapies, boosting the potential for personalized and more efficient treatments. Furthermore, growing awareness about the condition among healthcare professionals and patients has resulted in early diagnosis and timely intervention, leading to improved patient outcomes. Moreover, favorable government initiatives and increased healthcare spending have encouraged the expansion of healthcare infrastructure and access to treatment, further stimulating market growth. These factors collectively create a conducive environment for continuous advancements in Crohn's disease management, offering immense opportunities for pharmaceutical companies, research organizations, and healthcare providers alike.

Key Features of the Reports

  • The crohn’s disease market report provides granular level information about the market size, regional market share, historic market (2018-2022), and forecast (2023-2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

Crohns Disease Market Segmentation

By Procedures
  •  Colonoscopy, Flexible Sigmoidoscopy
  •  Computerized Tomography (CT)
  •  Magnetic Resonance Imaging (MRI)
  •  Capsule Endoscopy
  •  Double-Balloon Endoscopy
  •  Small Bowel Imaging
By Therapeutic Type
  • Non-surgical
  • Surgical
By Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online
By End User
  • Hospitals and Clinics
  • Research Institutes
  • Diagnostic Centres
  • Others

Frequently Asked Questions

The crohn’s disease market was valued at USD 10,783.6 million in 2022 and is expected to grow at 5.1% CAGR over the forecast period 2023 – 2029.

Key opportunities for the Crohn's Disease market include the growing demand for effective treatments, advancements in personalized therapies, increasing awareness, and favorable government support, fostering innovation and market expansion.

The key trends in the Crohn's Disease market include the rising adoption of biologics and immunomodulators, increasing focus on precision medicine, advancements in diagnostic technologies, and a shift towards patient-centric care approaches.

GlaxoSmithKline plc., F. Hoffmann-La Roche Ltd, Novartis AG, Eli Lilly and Company., AstraZeneca, Pfizer Inc., Takeda Pharmaceutical Company Limited., Bristol-Myers Squibb Company, Sanofi, Johnson & Johnson Services, Inc., Bayer AG, AbbVie Inc., Allergan, are a few prominent companies operating in the field of Crohn’s Disease market.

  • GlaxoSmithKline plc.
  • Hoffmann-La Roche Ltd
  • Novartis AG
  • Eli Lilly And Company.
  • Astrazeneca
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited.
  • Bristol-Myers Squibb Company
  • Sanofi
  • Johnson & Johnson Services, Inc.
  • Bayer AG
  • AbbVie Inc.
  • Allergan
  • Janssen Global Services, LLC
  • Takeda Pharmaceutical Company Limited
  • UCB S.A.
  • Ferring B.V.
  • Tillotts Pharma AG
  • Merck & Co., Inc.
  • Amgen Inc.

Adjacent Markets